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Abstract 
Gestational diabetes mellitus (GDM) is defined as hyperglycaemia that is diagnosed for the first time 
in the second or third trimester of pregnancy. It occurs in 1 in 7 pregnancies worldwide and is 
associated with increased risk of adverse perinatal outcome, in particular, infant birth weight that is 
large for gestational age, increased infant adiposity, preeclampsia and preterm delivery, and increased 
delivery by caesarean section. This review focuses on the controversy regarding screening and 
diagnosis of GDM following development of the International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) guidelines and the National Institute of Clinical Excellence (NICE) 2015 
guidelines. It reviews the most recent research in to diet and exercise modification in prevention and 
management of GDM, pharmacological management and post-partum management to delay and/or 
prevent progression to type 2 diabetes.    
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Introduction 
Gestational diabetes mellitus (GDM) is defined by the World Health Organisation as hyperglycaemia 
that is first recognised during pregnancy, or by the American Diabetes Association as “diabetes 
diagnosed in the second or third trimester of pregnancy that is not clearly overt diabetes”. It is 
associated with increased risk to the mother of preeclampsia, preterm delivery, caesarean section 
delivery and later development of overt diabetes. Risks to the offspring include increased adiposity 
and large for gestational age (LGA) defined as infant birth weight, adjusted for sex and gestational age, 
that is above the 90th percentile. While the severe perinatal complications associated with LGA, 
including asphyxia and death are rare, LGA infants are at increased longer-term risk of insulin 
resistance, obesity and diabetes later in life, with female offspring having an increased chance of 
developing GDM during future pregnancy.  
Epidemiology 
Gestational diabetes mellitus affects up to 5% of pregnancies in England and up to 1 in 7 pregnancies 
worldwide. Recognised risk factors include obesity and family history of type 2 diabetes mellitus 
(T2DM) which are steadily increasing in the background maternity population. The National Institute 
of Clinical Excellence (NICE) recognise additional risk factors including maternal ethnicity, advanced 
maternal age, multiple pregnancy and previous history of GDM or macrosomia (birthweight ≥ 4.5 kg). 
NICE guidance recommends that women with any one of these risk factors should undergo further 
diagnostic testing for gestational diabetes mellitus (Table 1). 
Screening  
There has been a longstanding debate about which women should be screened for GDM, all women 
(universal screening) or only high risk women (selective screening). The importance of screening was 
highlighted in the MBRRACE UK Confidential Enquiry into Antepartum Stillbirth two decades ago. 
However despite this, along with screening process being widely accepted by patients (1) and cost-
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effective, women are not always screened. In 2015 the MBRRACE UK enquiry identified that out of 
133 stillbirths, 69 (52%) women had one or more risk factors for GDM, but only 32 (46%) of women 
with risk factors were offered diagnostic testing. This discrepancy may not have been helped by the 
continued controversy between screening and diagnostic criteria, with no consensus among 
international bodies. The two main approaches of ‘universal’ and ‘selective’ screening and one step 
versus two step testing vary between clinics and across countries. 
One vs two step GDM screening 
The International Association of Diabetes and Pregnancy Study Groups (IADPSG) Consensus Panel 
supported by the World Health Organisation (WHO), the Australian Diabetes in Pregnancy Society 
(ADIPS) and the International Federation of Gynaecology and Obstetrics (FIGO) advise a universal 
diagnostic testing of all pregnant women at 24-28 weeks of gestation using a one-step approach of a 
75g oral glucose tolerance test (OGTT). The American Diabetes Association (ADA) also recommends a 
75g OGTT at the same gestation, or alternatively a two-step 50g glucose challenge test (GCT) followed 
by diagnostic 100g OGTT for women who screen positive. The two step approach can result in short 
delays to diagnosis and onset of treatment. However, a recent study of more than 81,000 women 
described only minimal delays, on average 10 days after the initial screen (1). A benefit of the two-
step approach is that women who screen negative to the 50g GCT, do not have to undergo an OGTT.  
Selective vs universal GDM screening 
The UK NICE guidelines suggest one step selective screening using identifiable risk factors. Women’s 
risk of developing gestational diabetes is assessed at a booking visit (table 1) and only those with 
recognised risk factors are offered a 2 hour 75g OGTT at 24-28 weeks gestation. An exception is 
women with previous GDM, who are offered self-monitoring of blood glucose or an early 75-g two-
hour OGTT, with a repeat 75g two-hour OGTT at 24-28 weeks if the early OGTT is normal. Selective 
risk factor screening approaches miss women with no apparent risk factors meaning that a proportion 
of women with GDM will not be treated. The proportion of women missed varies between populations 
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but can be up to 50%.  Griffin et al randomised 3742 Irish women to either a group screened for GDM 
if a risk factor was present, or to a universal screening group. Prevalence of GDM was 2.7% in the 
universal screening group compared to 1.45% in the risk factor screened group (P<0.03). The universal 
screening group also had higher rates of spontaneous vaginal delivery and lower rates of macrosomia. 
The universal screening group were diagnosed approximately 3 weeks earlier than the risk-factor 
screened group (30 versus 33 weeks’ gestation), which may have contributed to the differences in 
outcomes.  
The American Congress of Obstetricians and Gynaecologists (ACOG) guidelines agree that all women 
should be screened, but suggest this could be performed by assessment of the patient’s medical 
history, clinical risk factors or laboratory screening tests. 
Gestation of GDM screening 
The recommended gestation at which women are screened for GDM is 24-28 weeks gestation. The 
U.S Preventive Services Task Force (USPSTF) found little evidence on the benefits and detriments of 
screening prior to 24 weeks’ gestation.  Sovio et al investigated fetal growth in 4069 women who took 
part in the Pregnancy Outcome Prediction study in Cambridge, UK.  In women who developed GDM, 
excessive growth of fetal abdominal circumference was identified between 20 and 28 weeks gestation, 
preceding the diagnosis of GDM  (2). Therefore screening at 28 weeks may be too late to prevent fetal 
overgrowth especially in overweight and obese women, who had increased abdominal circumference 
by 20 weeks gestation.  As the proportion of women with overweight and obesity increases the risks 
and benefits of earlier screening will need to be re-evaluated.  
Random plasma glucose for GDM screening 
A national survey from the UK identified that 52% of respondents used random plasma glucose (RPG) 
measurements to screen for GDM, despite not being supported in clinical guidelines. Meek et al 
studied the use of random plasma glucose (RPG) to detect GDM in 17736 births in the UK. Women 
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were invited to have a random plasma glucose test at booking (typically 12-16 weeks gestation) as 
part of their usual care. The RPG at booking was more predictive than maternal age or BMI for 
identifying women at high risk of GDM. Even though it cannot replace the oral glucose tolerance test 
for screening of GDM, it may be useful in prioritising those who would benefit from early OGTT or to 
exclude women who do not need further investigation. NICE do not recommend the use of fasting 
plasma glucose, random blood glucose, glucose challenge test, HbA1c or urinalysis for GDM screening.  
 
Diagnosis 
As for screening there is no international consensus on diagnostic criteria for gestational diabetes. The 
landmark Hyperglycaemia and Adverse Pregnancy Outcome study (HAPO) published in 2008 described 
the risks of adverse outcomes associated with various degrees of maternal hyperglycaemia. This was 
a multinational, multicultural study of 25,000 women who had a 75-g oral glucose tolerance test 
(OGTT) during their third trimester of pregnancy. Results indicated strong, continuous associations of 
maternal glucose levels below those diagnostic of diabetes with increased birth weight and increased 
cord-blood serum C-peptide levels, suggesting that maternal glycaemia and associated maternal-fetal 
outcomes is a continuum, as opposed to an association reached at a particular threshold (3). 
Following the HAPO study, the International Association of Diabetes in Pregnancy Study Group 
(IADPSG) produced new guidelines in 2010 recommending lower fasting plasma glucose thresholds at 
1-hr ( ≥ 5.1 mmol/mol), 2-hr (≥  10.0 mmol/mol) and 3-hr (≥ 8.3 mmol/mol) after 75-g OGTT (table 2). 
Implementation of the one-step IADPSG criteria in Madrid, was associated with a 3.5 fold increased 
prevalence of GDM but was considered to be both clinically and cost effective compared to the 
traditional two-step Carpenter Coustan approach. There were reduced rates of caesarean section, 
large for gestational age infants and infant admission to neonatal intensive care units . 
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The IADPSG diagnostic values have been adopted by the WHO  and also by ADA who give the option 
of using either IADPSG criteria or diagnostic values using a two-step approach for diagnosing GDM .  
The National Institute of Clinical Excellence (NICE) produced new diagnostic guidelines for GDM in 
2015 varying from those recommended by the WHO and IADPSG. NICE recommends a higher 
threshold for fasting glucose ≥ 5.6 mmol/mol and a lower 2-hr value ≥ 7.8 mmol/mol, with no 
diagnostic threshold at 1 hour post OGTT . 
The IADPSG and NICE criteria were compared in a retrospective study of 25,543 births in the UK where 
originally 3848 OGTTs were performed. Retrospectively applying the 2015 NICE diagnostic and IADPSG 
criteria in these women, suggested that NICE criteria would have missed only a small number of 
women with GDM, who would have been detected using IADPSG criteria (0.5%). However, this group 
of women had a higher risk of having a large-for-gestational age infant, caesarean delivery and 
polyhydramnios compared with women with normal glucose tolerance. Women with the highest risk 
of having an LGA infant were those who “fell through the net”, suggesting that the IADPSG criteria 
identify women at substantial risk of complications who would not be identified by NICE 2015 criteria. 
Alternatively, 261 women were identified as GDM positive using the 2015 NICE criteria, but negative 
using IADPSG, with 2-hr post OGTT glucose values between 7.9-9.9mmol/l. These women did not have 
increased risk of pre-eclampsia or large for gestational age but they had an increased risk of 
polyhydramnios, compared to the reference population . 
 
GDM Management 
Following diagnosis of Gestational Diabetes Mellitus (GDM) the woman should be seen in a joint 
diabetes antenatal clinic within one week. The implications of the diagnosis of GDM, including short 
and long term risks to the mother and baby need to be explained as well as the importance of good 
blood glucose control to reduce pregnancy complications.  There is good evidence from randomised 
clinical trials for benefit of providing clinical treatment even to women with mild gestational diabetes 
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as this can reduce the risks of fetal overgrowth, shoulder dystocia, caesarean delivery and 
preeclampsia and, among women with more severe hyperglycaemia, treatment also reduces serious 
perinatal complications . 
Self-monitoring of blood glucose  
Recommended glucose control targets vary between organisations, but all are in agreement that 
blood glucose levels should be tightly controlled. Women with gestational diabetes should be taught 
how to self-monitor their blood glucose and use the same capillary plasma glucose targets as those 
with pre-existing diabetes. NICE recommends a fasting blood glucose of <5.3 mmol/l, 1 hour post-
meal ≤ 7.8 mmol/l and ≤ 6.4 mmol/l two hours after meals. The ACOG recommends the same fasting 
blood glucose as NICE, with a 1 hour post-meal target of <7.2 mmol/l, whereas the International 
Diabetes Federation (IDF) recommends fasting capillary glucose levels of 5.0-5.5 mmol/l, 1-hour post 
prandial <7.8 mmol/l and 2-hour post prandial of 6.7-7.1 mmol/l . Organisations are in agreement that 
it is important to maintain capillary plasma glucose levels above 4 mmol/l to avoid maternal 
hypoglycaemia . 
Diet and Lifestyle modification for treatment of GDM 
The best dietary intervention for GDM treatment is unclear. A 2013 Cochrane review of studies 
comparing low and high GI diets, high-fibre and energy restricted diets, high monounsaturated fat 
diets and high carbohydrate diets in a total of nine studies found no significant differences in benefit 
between the different dietary approaches . In clinical practice, diet recommendations tend to be 
towards a low carbohydrate-higher fat diet. However, these recommendations were recently 
challenged by a thought provoking pilot study of 12 diet-controlled overweight/obese women with 
GDM. Participants were randomised to a higher-complex carbohydrate/lower-fat (CHOICE) diet with 
60% carbohydrate, 25% fat, 15% protein or an isocaloric conventional low-carbohydrate/higher-fat 
(LC/CONV) diet with 40% carbohydrate, 45% fat, 15% protein. The aim was to explore potential 
differences in maternal insulin resistance, adipose tissue lipolysis and infant adiposity before 
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embarking on a longer term trial. After seven weeks women on the high carbohydrate/low fat CHOICE 
diet had decreased fasting glucose and free fatty acids with consistent or improved insulin resistance 
compared to women on the conventional low carbohydrate/high fat diet .  
Thus as in other aspects of GDM screening and diagnosis, there is no consensus about what are the 
most effective dietary approaches for optimal maternal and fetal health outcomes during GDM 
pregnancy.  
Pharmacological treatment (Insulin and oral hypoglycaemic agents)  
Metformin improves insulin sensitivity, is not associated with hypoglycaemia or maternal weight gain 
and is orally administered which is often more acceptable for women than insulin injections. However, 
metformin does cross the placenta and has wide ranging actions which affect a diverse range of 
mitochondrial, proliferative, hepatic, and metabolic signalling pathways for which the longer term 
consequences and potential for fetal programing effects are largely unknown.   
A randomised control trial comparing metformin with insulin treatment in 751 women in Australia 
and New Zealand found that the incidence of neonatal complications did not differ between groups, 
however the metformin group had less episodes of hypoglycaemia and increased rate of preterm birth 
(before 37 weeks). There was no difference in neonatal anthropometic measures or measurements of 
umbilical-cord serum insulin concentrations suggesting that both metformin and insulin had the same 
effect on fetal growth and hypoglycaemia. Women in the metformin treated group experienced less 
weight gain during pregnancy which may be beneficial in reducing women’s future risk of developing 
T2DM. Interestingly 46% of women taking metformin required supplemental insulin suggesting that 
many women are unable to maintain target glucose levels on metformin alone.  Additionally, children 
of women in the metformin group at two years old had increased fat stored in subcutaneous sites 
(larger upper-arm circumferences and subscapular skinfolds) which may in turn mean there was lower 
visceral body fat compared to children of women randomised to insulin, despite similar birthweight . 
Offspring of mothers who were treated with metformin for polycystic ovarian syndrome have also 
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shown a reassuring lack of effect on motor or social development at 18 months . A more recent review 
of metformin in 2165 women with GDM or type 2 diabetes found that metformin lowered the risk 
of neonatal hypoglycaemia, large for gestational age babies, pregnancy-induced hypertension 
and gestational weight gain with no short-term adverse effects on maternal-infant health 
outcomes, but limited long-term follow-up information . 
 
NICE 2015 guidelines recommend using metformin in women with gestational diabetes mellitus if 
blood glucose targets do not meet the target ranges within 1-2 weeks of changes to diet and exercise. 
Insulin is recommended instead of metformin if metformin is contraindicated, cannot be tolerated or 
if glucose levels remain outside the target range. Immediate treatment with insulin is recommended 
for women with fasting plasma glucose level of 7.0 mmol/l and should be considered if 6.0 mmol/l in 
addition to complications of macrosomia or polyhydramnios. Glibenclamide is only recommended if 
insulin therapy is declined and blood glucose targets are not achieved with metformin or metformin 
is not tolerated .  The ACOG guidance gives no preference to insulin or oral agent for management of 
GDM  although a recent systematic review and meta-analysis involving 2509 women with GDM 
suggest that glibenclamide is “clearly inferior” to both insulin and metformin and should not be used 
for treatment of GDM if insulin or metformin are available (4). 
More intensive dietary intervention and/or greater weight loss, performed in selected populations of 
women at highest risk for GDM are required to evaluate the efficacy of dietary intervention for GDM 
prevention. 
 
Prevention of GDM 
A western diet (high in calories, processed meat, saturated fat and refined carbohydrate) has been 
identified as a possible contributing factor for developing both type 2 and gestational diabetes 
mellitus. Diet and lifestyle modification is thus the first-line management for both treating women 
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with gestational diabetes and for GDM prevention. However a 2012 meta-analysis of 44 diet and 
lifestyle randomised-controlled trials in a total of 7,278 pregnant women found that even though diet, 
physical activity or a mixed diet and lifestyle approach reduced maternal gestational weight gain (up 
to 3.8 kg reduction with dietary intervention), there was no significant reduction in the incidence of 
gestational diabetes in these study populations .  
Diet 
Low glycaemic index foods are often recommended in management of type 2 and gestational diabetes 
mellitus to help manage glucose levels, however a low glycaemic index diet has not been seen to help 
prevent the onset of gestational diabetes. Markovic et al’s study of 139 women who were identified 
as having a high risk of GDM  were randomised to one of two healthy diets of similar macronutrient 
composition, however one group had a low GI (target GI ≤50) diet compared to a high fibre, moderate 
GI diet. There was no difference in rates of small or large for gestational age infants, mode of delivery 
or incidence of GDM. 
Schoenaker et al’s systematic review of observational studies investigating the role of energy, 
nutrients and dietary patterns in the development of gestational diabetes mellitus supported a diet 
limiting saturated fat and cholesterol as part of an overall balanced diet to reduce the risk of 
developing GDM, but concluded that further large prospective studies are necessary . 
Lifestyle 
Small studies that explored the use of physical activity in reducing the incidence of GDM such as The 
Finnish Gestational Diabetes Prevention Study (RADIEL) found beneficial results from those who had 
lifestyle counselling. RADIEL randomised 293 high-risk women with a history of GDM and or a pre-
pregnancy BMI of 30kg/m2 to an intervention or control group. The intervention participants 
received individualized lifestyle counselling with a study nurse on three occasions during pregnancy 
and one two-hour group session with a dietitian. They were encouraged to aim for a minimum of 150 
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minutes of moderate-intensity physical activity per week. Although the between group differences 
were small, women in the intervention group increased leisure time physical activity, had better diet 
quality and lower gestational weight gain (0.58kg). There were fewer new cases of GDM in the 
intervention group (20 versus 27; p=0.04) (5).  
The DALI lifestyle study compared the effectiveness of three lifestyle interventions (healthy eating, 
physical activity and both together) with usual care in reducing the risk of developing GDM in 436 
women. All participants were less than 20 weeks gestation and had a BMI ≥ 29 kg/m2. Women who 
were in the healthy eating with physical activity group achieved less gestational weight gain 
throughout pregnancy than any of the other groups. There was no improvement in fasting, post-load 
glucose or insulin concentrations in any group, suggestive that lifestyle change alone is unlikely to 
prevent GDM in women who have a BMI ≥ 29 kg/m2(6).  
Unfortunately the potentially promising suggestion that a lifestyle intervention can prevent GDM in 
the RADIEL study was also not replicated in larger randomised controlled trials such as UPBEAT (7) and 
LIMIT  . 
UK Pregnancies Better Eating and Activity Trial (the UPBEAT study)  
The objective of the UPBEAT study was to assess whether behavioural interventions would be able to 
reduce the incidence of gestational diabetes (GDM) and large-for-gestational-age infants in women 
who are obese. 1,555 women with a BMI  30kg/m2 from eight hospitals in multi-ethnic, inner-city 
locations in the UK were randomised to either a behavioural intervention or standard antenatal care. 
Consisting of nine, one-hour group or individual sessions, the interventions addressed self-monitoring, 
identification, and problem-solving of barriers to behaviour change. Participants in the intervention 
group were given information recommending foods and, physical activity, a log book for recording 
SMART (specific, measurable, achievable, relevant, time-specific) goals and a DVD of an exercise 
regimen appropriate for pregnancy.  GDM was measured by a 75-g oral glucose tolerance test (OGTT) 
at 28±1 weeks gestation and diagnosed using the IADPSG criteria (fasting glucose of  5.1 mmol/L, 1-
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hr glucose 10.0 mmol/L or 2-hr glucose 8.5 mmol/L). They found that the incidence of gestational 
diabetes and of large-for-gestational age infants was similar between groups. There were 172 (26%) 
new GDM cases in standard care and 160 (25%) GDM cases in the intervention arm (P=0.68), with low 
rates of LGA (8% and 9% respectively). However, there were some potential benefits, as women in the 
lifestyle intervention group had less gestational weight gain and a lower sum of maternal skinfold 
thickness (7).  
Similarly the Australian LIMIT randomised controlled trial recruited 2212 overweight and obese 
pregnant women (BMI >25kg/m2) between 10-20 weeks gestation to either a comprehensive diet and 
lifestyle intervention or standard antenatal care. Women who were randomised to the intervention 
and control groups had similar rates of gestational diabetes (148 cases or 14% vs 120 cases or 11%; 
p=0.11) and large-for-gestational age infants (19% vs 20%; p=0.24) . The intervention did however 
reduce the risk of large infant birth weight (15% vs 19%; p0.04 for birth weight >4000g). 
 
Pharmcological prevention of GDM 
The effect of metformin on maternal and fetal outcomes in obese pregnant women were considered 
in the EMPOWaR (8) and MOP (9) trials. EMPOWaR randomised 449 women without diabetes but with 
a BMI  30kg/m2 from 15 UK hospitals to receive metformin or placebo. Metformin 500mg or matched 
placebo tablets were taken in a dose of up to five tablets in two to three divided doses initiated 
between 12-16 weeks’ gestation and continued until the delivery of the baby. In this setting metformin 
was ineffective for reducing offspring birthweight or maternal insulin resistance . 
However, The Metformin in Obese Nondiabetic Pregnant Women (MOP) trial of 400 women without 
diabetes, but with a higher maternal BMI>35kg/m2 found that maternal gestational weight gain (4.6 vs 
6.3kg; p<0.001) and incidence of preeclampsia (3% vs 11%; p=0.001) were both significantly lower in 
the metformin group, possibly due to earlier metformin initiation, better compliance and/or higher 
maternal BMI at baseline (9). 
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Follow-up and prevention of type 2 diabetes mellitus 
The incidence of type 2 diabetes mellitus (T2DM) in women with GDM is 70% higher than in the 
background population with a 50 % to 70% rate of progression from GDM to T2DM over 5-10 years of 
follow-up depending on ethnicity. NICE 2015 guidelines recommend testing blood glucose in women 
who were diagnosed with GDM to exclude persisting hyperglycaemia before they are transferred to 
community care. They advise that women be offered a fasting plasma glucose at 6-13 weeks 
postpartum to exclude diabetes, instead of routinely offering a 75 g OGTT . 
The Gestational Diabetes effects on Moms (GEM) randomised control study of 2,280 women with 
GDM from 44 clinics compared strategies to minimise post-partum weight retention. Women who 
were in the diabetes prevention programme (DPP) lifestyle intervention group received a letter and 
up to 13 follow up phone calls between six weeks and six months after delivery. The intervention 
incorporated personalised weight, exercise and diet goals although the methods used to achieve these 
goals were in line with women’s preferences using motivational interviewing. At six months post-
partum, women in the intervention group retained less weight (0.4 vs 1.0kg); were more likely to meet 
their pre-specified weight goals than women in usual care (31% vs 24%), and did more vigorous-
intensity physical activity (15 minutes/week) suggesting that there is potential benefit of intensive 
diet and lifestyle interventions for weight loss after pregnancy (10). 
Another study of 4,502 women with a history of gestational diabetes were followed from 1991 to 2011 
and 722 women developed type 2 diabetes mellitus. The authors observed that women who had a 
low-carbohydrate diet (40% carbohydrate) with high protein and fat intake mainly from animal source 
foods were at an increased risk of developing type 2 diabetes mellitus, and concluded that this 
particular diet may be associated with a higher risk of developing type 2 diabetes, whereas low 
carbohydrate diet with high protein and fat from plant-source foods was not significantly associated 
with risk of type 2 diabetes . 
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Conclusion 
The incidence of gestational diabetes is increasing and is associated with increased maternal and 
neonatal risks. Recommended screening and diagnostic criteria guidelines vary between 
organisations. First line management of gestational diabetes is diet and lifestyle modification, which 
seems modestly effective for limiting maternal gestational weight gain despite limited research 
pointing to which dietary and/or behavioural interventions are most effective. Metformin and/or 
Insulin are recommended as second line treatments if glucose levels remain above target. Behavioural 
interventions may be beneficial at reducing the risk of developing type 2 diabetes in this high risk 
cohort of women and follow-up with prevention of developing type 2 diabetes is an important part of 
the management for gestational diabetes.  
 
Practice Points 
 Screening for GDM is recommended, however there is controversy as to whether selected 
risk-factor based screening or universal screening approaches should be used 
 Diagnostic criteria for GDM vary between organisations.  
 Fetal growth acceleration is already apparent at 28 weeks gestation so earlier detection and 
treatment of GDM may be needed for optimal infant outcomes. 
 Current recommendation for GDM is diet and lifestyle modification with pharmacological 
treatment (metformin and/or insulin) if glucose targets are not achieved. 
 Glibenclamide should not be used for treatment of GDM if insulin or metformin are available 
(4) 
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 Large RCTs have found little benefit from diet and lifestyle modification or pharmacological 
treatment with metformin for obese women without diabetes either for GDM prevention 
and/or reducing neonatal growth acceleration. 
 Whilst metformin appears effective at limiting maternal weight gain, more data are required 
regarding longer term impacts on embryonic, placental and placental development 
 Women who have had gestational diabetes should be followed up after pregnancy and 
advised on diet and lifestyle modifications in order to reduce their risk of recurrent gestational 
diabetes and/or developing type 2 diabetes.  
Further reading - https://www.nice.org.uk/guidance/ng3 
1. If fasting glucose levels are above target after 1-2 weeks of dietary intervention what is the 
recommended first line treatment in GDM pregnancy  
a. Increased physical activity  
b. Glibenclamide 
c. Long or intermediate acting insulin 
d. Metformin 
e. Fast acting insulin before evening meal 
2. In a woman with previous GDM which of the following is effective for reducing recurrent 
GDM/risk of progression to type 2 diabetes 
a.  Metformin 
b. Glibencalmide 
c. Diet and Lifestyle  
d. Exclusive breastfeeding for 6 months duration 
e. Insulin 
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Table 1: National Institute of Clinical Excellence screening criteria for gestational diabetes mellitus 
 BMI above 30 kg/m2 
 Previous macrosomic baby weighting 4.5 kg or above 
 Previous gestational diabetes 
 Family history of diabetes (first-degree relative with diabetes) 
 Minority ethnic family origin with a high prevalence of diabetes 
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Table 2: Screening and Diagnostic criteria for GDM 
Organisation Year proposed Approach Gestation Glucose Challenge 
Glucose threshold mg/dL (mmol/L) 
Fasting 1 hr 2 hr 3 hr 
American Diabetes 
Association (ADA) 
2016 1 or 2 step 24-28 weeks 1 step:  75g OGTT  
OR 
2 step: 50g (nonfasting) 
screen followed by a 3h 
100g OGTT for those who 
screen positive  
≥ 92 (5.1) 
 
≥ 95 (5.3) 
≥ 180 (10.0) 
 
≥ 180 (10.0) 
≥ 153 (8.5) 
 
≥ 155 (8.6) 
 
 
≥ 140 (7.8) 
World Health 
Organization (WHO) 
2013 
(revised, same as 
IADPSG) 
1 step 
 
Any gestation 75g OGTT 92-125 
(5.1-6.9) 
≥ 180 (10.0) 153-199 
(8.5-11.0) 
 
National Institute for 
Health and Care 
Excellence (NICE) 
2015 1 step Previous GDM: 
booking and again 
at 24-28 weeks 
No Previous GDM 
but other risk 
factors: 24-28 
weeks) 
75g OGTT 2 hour ≥ 120 (5.6)  ≥ 160 (7.8)  
International 
Association of 
Diabetes and 
Pregnancy Study 
Groups (IADPSG) 
2010 1 step 24-28 weeks 75g OGTT ≥  92 (5.1) ≥ 180 (10.0) ≥  153 (8.5) 
 
 
American College of 
Obstetricians and 
Gynecologists (ACOG) 
2013 2 step  50g (nonfasting) screen 
followed by a 3h 100g OGTT 
for those who screen 
positive 
≥ 95 (5.3) ≥ 180 (10.0) ≥ 154 (8.6) ≥  140 (7.8) 
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